FR2766715B1 - PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE - Google Patents

PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE

Info

Publication number
FR2766715B1
FR2766715B1 FR9709975A FR9709975A FR2766715B1 FR 2766715 B1 FR2766715 B1 FR 2766715B1 FR 9709975 A FR9709975 A FR 9709975A FR 9709975 A FR9709975 A FR 9709975A FR 2766715 B1 FR2766715 B1 FR 2766715B1
Authority
FR
France
Prior art keywords
viral
association
double
separate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9709975A
Other languages
French (fr)
Other versions
FR2766715A1 (en
Inventor
De Paillette Evelyne Deschamps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to FR9709975A priority Critical patent/FR2766715B1/en
Priority to ARP980103723A priority patent/AR013269A1/en
Priority to TW087112434A priority patent/TW589189B/en
Priority to ZA986903A priority patent/ZA986903B/en
Priority to PCT/FR1998/001727 priority patent/WO1999007409A1/en
Priority to BR9811121-3A priority patent/BR9811121A/en
Priority to AT98941527T priority patent/ATE211393T1/en
Priority to EP98941527A priority patent/EP1001801B1/en
Priority to JP2000506998A priority patent/JP2001513514A/en
Priority to ES98941527T priority patent/ES2171039T3/en
Priority to PT98941527T priority patent/PT1001801E/en
Priority to PL98338377A priority patent/PL338377A1/en
Priority to DE69803391T priority patent/DE69803391T2/en
Priority to DK98941527T priority patent/DK1001801T3/en
Priority to CA002299554A priority patent/CA2299554A1/en
Priority to KR1020007001163A priority patent/KR20010022572A/en
Priority to CN98808902A priority patent/CN1269725A/en
Priority to US09/485,086 priority patent/US6509154B1/en
Priority to IL13427598A priority patent/IL134275A0/en
Priority to HU0003384A priority patent/HUP0003384A3/en
Priority to AU89872/98A priority patent/AU750026B2/en
Priority to MYPI98003552A priority patent/MY132954A/en
Publication of FR2766715A1 publication Critical patent/FR2766715A1/en
Priority to NO20000555A priority patent/NO20000555L/en
Application granted granted Critical
Publication of FR2766715B1 publication Critical patent/FR2766715B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
FR9709975A 1997-08-04 1997-08-04 PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE Expired - Fee Related FR2766715B1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR9709975A FR2766715B1 (en) 1997-08-04 1997-08-04 PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE
ARP980103723A AR013269A1 (en) 1997-08-04 1998-07-29 PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS
TW087112434A TW589189B (en) 1997-08-04 1998-07-29 Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
ZA986903A ZA986903B (en) 1997-08-04 1998-07-31 Product containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease notably of viral hepatitis
KR1020007001163A KR20010022572A (en) 1997-08-04 1998-08-03 Product Comprising at Least a Double Stranded RNA Combined with at Least an Antiviral Agent
AT98941527T ATE211393T1 (en) 1997-08-04 1998-08-03 COMPOSITION CONTAINING AT LEAST ONE DOUBLE STRAND RNA AND AT LEAST ONE INTERFERON FOR THE TREATMENT OF VIRAL HEPATITIS
EP98941527A EP1001801B1 (en) 1997-08-04 1998-08-03 Product comprising at least a double stranded rna combined with at least an interferon for the treatment of viral hepatitis
JP2000506998A JP2001513514A (en) 1997-08-04 1998-08-03 Product containing at least one double-stranded RNA (dsRNA) in combination with at least one antiviral agent
ES98941527T ES2171039T3 (en) 1997-08-04 1998-08-03 PRODUCT THAT INCLUDES AT LEAST A double-stranded RNA IN ASSOCIATION WITH AT LEAST ONE INTERFER FOR THE TREATMENT OF VIRAL HEPATITIS.
PT98941527T PT1001801E (en) 1997-08-04 1998-08-03 A PRODUCT UNDERTAKING AT LEAST A DOUBLE SPIRAL RNA IN ASSOCIATION WITH AT LEAST AN INTERFERENCE FOR THE TREATMENT OF VIRAL HEPATITIS
PL98338377A PL338377A1 (en) 1997-08-04 1998-08-03 Product containing at least one double-string rna (ds rna) in combination with at least one antiviral agent
DE69803391T DE69803391T2 (en) 1997-08-04 1998-08-03 COMPOSITION CONTAINING AT LEAST ONE DOUBLE STRANDED RNA AND AT LEAST ONE INTERFERON FOR THE TREATMENT OF VIRAL HEPATITIS
PCT/FR1998/001727 WO1999007409A1 (en) 1997-08-04 1998-08-03 Product comprising at least a double stranded rna combined with at least an antiviral agent
CA002299554A CA2299554A1 (en) 1997-08-04 1998-08-03 Product comprising at least a double stranded rna combined with at least an antiviral agent
BR9811121-3A BR9811121A (en) 1997-08-04 1998-08-03 Product, pharmaceutical composition, and use of a product
CN98808902A CN1269725A (en) 1997-08-04 1998-08-03 Product comprising at least double stranded RNA combined with at least an antiviral agent
US09/485,086 US6509154B1 (en) 1997-08-04 1998-08-03 Product comprising at least a double stranded RNA combined with at least an antiviral agent
IL13427598A IL134275A0 (en) 1997-08-04 1998-08-03 Product comprising at least a double standed rna combined with at least an antiviral agent
HU0003384A HUP0003384A3 (en) 1997-08-04 1998-08-03 Product comprising at least a double stranded rna combined with at least an antiviral agent
AU89872/98A AU750026B2 (en) 1997-08-04 1998-08-03 Product comprising at least a double stranded RNA combined with at least an antiviral agent
DK98941527T DK1001801T3 (en) 1997-08-04 1998-08-03 Product comprising at least one double-chain RNA combined with at least one interferon for the treatment of viral hepatitis
MYPI98003552A MY132954A (en) 1997-08-04 1998-08-04 Product containing at least one double-stranded rna combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
NO20000555A NO20000555L (en) 1997-08-04 2000-02-03 Product containing at least one double stranded RNA combined with at least one antiviral agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9709975A FR2766715B1 (en) 1997-08-04 1997-08-04 PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE

Publications (2)

Publication Number Publication Date
FR2766715A1 FR2766715A1 (en) 1999-02-05
FR2766715B1 true FR2766715B1 (en) 2001-02-16

Family

ID=9510013

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9709975A Expired - Fee Related FR2766715B1 (en) 1997-08-04 1997-08-04 PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE

Country Status (2)

Country Link
FR (1) FR2766715B1 (en)
ZA (1) ZA986903B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
PH24467A (en) * 1987-03-03 1990-07-18 Hem Res Inc Synergistics interplay of lymphokines and dsrnas
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
AU1820588A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function
ATE122402T1 (en) * 1987-09-04 1995-05-15 Hem Pharma Corp DIAGNOSIS OF DOUBLE-STRANDED RNA DEFICIENCIES.
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis

Also Published As

Publication number Publication date
ZA986903B (en) 1999-01-28
FR2766715A1 (en) 1999-02-05

Similar Documents

Publication Publication Date Title
MA26790A1 (en) DIETETIC OR PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF HYPER-OXALURIA
FR09C0055I2 (en) PHARMACEUTICAL COMPOSITION COMPRISING PIOGLITAZONE AND GLIMEPIRIDE FOR USE IN THE TREATMENT OF DIABETES
FR2734483B1 (en) PHARMACEUTICAL ADMINISTRATION FORM COMPRISING OXYBUTYNIN
BR9811121A (en) Product, pharmaceutical composition, and use of a product
MA25820A1 (en) COMBINATIONS OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETES MELLITUS.
MA26608A1 (en) PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART FAILURE.
TR199600873A2 (en) Substituted sulfonimidamides, the method for making them, their use as drugs or diagnostic agents, and also medicaments containing them.
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
DZ3014A1 (en) Medicines for the treatment of hypertension.
FR2716075B1 (en) A method for enhancing the effectiveness of an agricultural chemical, enhancer and enhancer composition used in this method and agricultural chemical composition comprising this enhancer.
DZ3141A1 (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy.
FR2717080B1 (en) Use of eipriprodil and its enantiomers for the preparation of medicaments useful in the treatment of peripheral neuropathies and central neurodegenerative diseases.
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
FR2766715B1 (en) PRODUCT INCLUDING AT LEAST DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR OVER TIME, IN THE TREATMENT OF A VIRAL DISEASE
DZ2564A1 (en) Pharmaceutical compositions for the treatment of diabetes mellitus and associated conditions.
FR2768344B1 (en) PRODUCT COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE
DZ1988A1 (en) Combination therapy for the treatment of winter.
FR2768345B1 (en) PRODUCT COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE ANTI-VIRAL AGENT FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, IN PARTICULAR OF A VIRAL HEPATITIS
FR2720944B1 (en) Therapeutic or dietetic composition in the form of a medicated gel for administration to pets.
FR2826261B1 (en) TOPICAL COMPOSITION COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE
FR2766711B1 (en) PRODUCT COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA IN ASSOCIATION WITH AT LEAST ONE DEVIRE OF 6-BENZYLURACIL FOR SIMULTANEOUS THERAPEUTIC USE, SEPARATE OR SPREAD OVER TIME
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
FR2733913B1 (en) DNA SEQUENCE AS A MEDICAMENT, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2709964B1 (en) Antiviral pharmaceutical compositions proposed in the treatment of AIDS and Herpes.

Legal Events

Date Code Title Description
ST Notification of lapse